预约演示
更新于：2026-08-22
Voglibose
伏格列波糖
更新于：2026-08-22
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C10H21NO7 |
InChIKeyFZNCGRZWXLXZSZ-CIQUZCHMSA-N |
CAS号83480-29-9 |
关联
84
项与 伏格列波糖 相关的临床试验CTR20262405
伏格列波糖口崩片生物等效性试验
CTR20252676
伏格列波糖口崩片人体生物等效性研究
CTRI/2025/04/085924
Study Of Efficacy And Safety Of Fixed Drug Combination Of Glimepiride, Metformin And Voglibose In Type 2 Diabetes Patients Inadequately Controlled On Dual Combination. - GLIVME
100 项与 伏格列波糖 相关的临床结果
登录后查看更多信息
100 项与 伏格列波糖 相关的转化医学
登录后查看更多信息
100 项与 伏格列波糖 相关的专利（医药）
登录后查看更多信息
547
项与 伏格列波糖 相关的文献（医药）2026-12-01JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
Evaluation of novel topiramate–phenolic acid conjugates as potent pancreatic α-amylase inhibitors: in vitro and in silico insights
Article
作者: Sharma, Tripti ; Biswas, Abanish ; Chandra, Anshuman ; Padhy, Ipsa
Inhibition of carbohydrate digesting enzymes like pancreatic α-amylase has proven to be an effective strategy in countering postprandial hyperglycaemia. However, unwanted adverse effects associated with current therapies, such as ACB, voglibose, and miglitol, have necessitated the development of safer and more effective alternatives. These challenges have prompted growing interest in natural product scaffolds, particularly phenolic compounds, which exhibit favourable safety profiles and multifaceted enzyme inhibition. In this context, the strategic design of molecular conjugates integrating bioactive phenolics offers a promising route to enhance inhibitory potency, binding specificity, and therapeutic relevance. Reportedly, molecular hybrids with chalcone, phenolic acid, coumarin and polyphenol backbone exhibited impressive antioxidant and potent inhibition against digestive enzymes. In the quest of developing novel anti-hyperglycaemic agents, we report in vitro and in silico evaluation of the novel TPAC as potential pancreatic α-amylase inhibitors in the present work. Among the ten conjugates, T5 (IC50 = 50.65 ± 0.76 µM) exhibited strong inhibition against PPA which was comparable to positive control ACB (24.81 ± 0.98 µM). Computational binding analysis revealed binding of T5 to HPA (PDB ID: 2QV4) by interacting with the amino acid residues and distorting the receptor's catalytic site conformation. Furthermore, the conformational dynamic studies and electron density driven simulations established the stability and high reactivity of T5 within the ligand-receptor complex. The in silico studies corroborated the in vitro enzyme inhibition results, reinforcing the mechanistic insights into ligand-receptor interactions. Taken together, the experimental and computational results indicate that T5 merits further investigation as a candidate molecule targeting pancreatic α-amylase for the management of T2D .
2026-05-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Design, synthesis of novel methyl-glycosyl furanose based sulfonium type α-glucosidase inhibitors with potent antihyperglycemic activity
Article
作者: Xu, Bohang ; Xie, Weijia ; Tanabe, Genzoh ; Li, Yaojia ; Li, Wei ; Yao, Xuesong ; Li, Yu ; Sun, Xiaolian ; He, Xiaosong ; Muraoka, Osamu ; Jin, Shuqing
Developing effective α-glucosidase inhibitors is critical for managing hyperglycemia in individuals with high-carbohydrate diets; however, current drugs exhibit limitations in both efficacy and tolerability. In the present study, 25 derivatives of neoponkoranol, an active sulfonium type α-glucosidase inhibitor identified from Genus Salacia were synthesized. These compounds containing a methyl-glycosyl furanose scaffold modified with various hydrophobic groups at the 5'-O-position, were characterized using HRMS and NMR spectroscopy. Biological evaluations demonstrated a selectively enhanced maltase inhibition profile while maintaining broad-spectrum activity. Most sulfonium salts exhibited potent inhibitory activity against maltase and sucrase with IC50 values ranging from 0.14 to 2.21 μM; these potencies are comparable to or superior to those of the positive controls acarbose and voglibose. In addition, the designed derivatives also exhibited strong isomaltase inhibitory activities whereas acarbose was almost inactive against this enzyme. Compound LY-23 emerged as the most potent inhibitor with maltase IC50 = 0.18 ± 0.03 μM, sucrase IC50 = 0.14 ± 0.01 μM, and isomaltase IC50 = 0.51 ± 0.06 μM. Mechanism studies characterized LY-23 as a competitive inhibitor. Molecular docking along with 3D fluorescence and CD spectral analyses indicated that LY-23 binds to α-glucosidase, inducing secondary structural and conformational changes in the enzyme. Furthermore, LY-23 showed no significant cytotoxicity in HEK293T and L02 cells. Remarkably, in vivo studies revealed that the oral administration of LY-23 (1.0 or 10.0 mg/kg) effectively reduced postprandial blood glucose levels in normal ICR mice following maltose or sucrose loading, with an efficacy comparable to that of voglibose (1.0 mg/kg) and acarbose (20.0 mg/kg), respectively. These findings highlight LY-23 as a promising candidate for the development of novel α-glucosidase inhibitors with antihyperglycemic properties.
2026-04-06Cureus Journal of Medical Science
Effectiveness of Nutritional Therapy Versus Alpha-Glucosidase Inhibitors in Postprandial Glycemia Control in an Indian Subpopulation of Patients With Type 2 Diabetes: A Prospective Crossover Study
Article
作者: Hanchinal, Shivaraj S ; Shambhukari, Praveen Rao ; Gaddam, Anudeep
BACKGROUND:
Type 2 diabetes mellitus (T2DM) poses a significant global health challenge, impacting millions of people worldwide. While many studies focus on HbA1c levels, there remains a need to evaluate glycemic variability and postprandial glucose (PPG) excursions. Therefore, this study was conducted to assess and compare the safety and effectiveness of nutritional therapy and alpha-glucosidase inhibitors in achieving rapid PPG stabilization in an Indian subpopulation of patients with T2DM.
METHODS:
This short-term open-label study included T2DM patients uncontrolled on metformin and sulfonylurea. The study enrolled 60 participants (40 males, 20 females) with a mean age of 54.06 ± 6.04 years, with the majority being 30-60 years of age (85%). All patients were given intermittent medical nutritional therapy (low glycemic index (LGI) diet) and alpha-glucosidase inhibitors (AGIs; acarbose, voglibose) to manage postprandial glycemia. A rotational design ensured that each group experienced all interventions in varying sequences for a comprehensive analysis of their effects. Glycemic responses were assessed using finger-stick capillary glucose measurements and continuous glucose monitoring (CGM) to evaluate postprandial and 24-hour glycemic variability.
RESULTS:
Postprandial mean glucose levels were significantly reduced with all interventions (p<0.05), with the highest reduction observed with acarbose. Between AGIs, the adverse effects were similar between medications. The 24-hour mean glucose levels, mean amplitude of glycemic excursion, and area under the curve for 24-hour glycemic fluctuations were significantly lower with interventions, especially acarbose.
CONCLUSION:
We conclude that AGIs and LGI diets effectively reduce postprandial glucose, especially in Indian T2DM patients consuming high-carbohydrate diets with a high glycemic load.
100 项与 伏格列波糖 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病 | 中国 | 2001-01-01 | |
| 糖尿病 | 中国 | 2001-01-01 | |
| 2型糖尿病 | 日本 | 1994-07-01 | |
| 高血糖 | 日本 | 1994-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 葡萄糖耐受不良 | 临床阶段不明 | 中国 | 2008-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 494 | 廠願鑰窪繭觸製醖獵顧(夢遞遞構糧鑰積襯齋繭) = 範簾範網鬱鹹觸觸築糧 鏇醖夢鬱選鹽壓廠憲醖 (構觸夢膚簾願鏇衊願鬱, 0.0742) 更多 | - | 2019-02-04 | |||
廠願鑰窪繭觸製醖獵顧(夢遞遞構糧鑰積襯齋繭) = 餘顧憲簾餘願窪壓夢範 鏇醖夢鬱選鹽壓廠憲醖 (構觸夢膚簾願鏇衊願鬱, 0.0764) 更多 | |||||||
临床4期 | 197 | 衊衊糧積艱鏇繭淵獵範 = 鬱艱襯製膚鏇襯憲壓糧 淵艱繭醖艱選膚醖艱範 (網網淵積構積顧廠鹹觸, 艱繭範淵壓壓選鏇蓋網 ~ 夢憲遞遞窪網顧蓋鹽繭) 更多 | - | 2015-04-09 | |||
临床1期 | - | 22 | Metformin | 膚淵簾醖簾構齋選糧襯(壓憲積積築廠餘鏇廠衊): geometric mean ratio = 0.99 (90% CI, 0.92 ~ 1.06), P-Value = > 0.05 更多 | - | 2014-11-01 | |
Metformin + Voglibose | |||||||
临床3期 | 133 | Sitagliptin 50 mg/day | 齋醖襯網網鑰餘憲積窪(襯廠壓製夢鬱艱憲夢積) = 顧襯衊醖鏇鬱網鏇蓋製 醖夢簾壓鬱鬱積艱繭範 (醖襯繭繭製醖製鬱艱鹽 ) 更多 | - | 2013-11-27 | ||
临床3期 | 319 | Sitagliptin 50 mg once daily | 艱築簾廠鏇範構糧繭顧(遞淵鬱醖製鏇遞齋簾夢) = 淵願襯夢網憲鬱餘願築 鬱憲艱獵艱壓鬱選衊夢 (簾鏇艱構願糧壓範壓醖, -0.8 ~ -0.6) 更多 | 积极 | 2010-07-01 | ||
Voglibose 0.2 mg thrice daily | 艱築簾廠鏇範構糧繭顧(遞淵鬱醖製鏇遞齋簾夢) = 鹹鹹簾鑰選繭糧窪憲淵 鬱憲艱獵艱壓鬱選衊夢 (簾鏇艱構願糧壓範壓醖, -0.4 ~ -0.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用